CLINICAL TRIALS PROFILE FOR AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
✉ Email this page to a colleague
All Clinical Trials for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00651118 ↗ | A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2008-03-01 | The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone) |
| NCT00660517 ↗ | A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2007-12-01 | The purpose of this study is to determine if two allergy medications (azelastine and fluticasone) are more effective than placebo or either medication alone (azelastine or fluticasone) |
| NCT00740792 ↗ | A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2008-08-01 | The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone) |
| NCT00883168 ↗ | A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2009-04-01 | The purpose of this study is to determine if the combination of two allergy medications (formulated azelastine/fluticasone product)is more effective than placebo or either component medication alone (azelastine or fluticasone). |
| NCT01190852 ↗ | Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays | Completed | ClinResearch, GmbH | Phase 1 | 2010-08-01 | The primary objective is to assess the effect of fluticasone propionate (FLU) on the relative bioavailability (AUC0-∞) of azelastine hydrochloride (AZE) when administered as fixed AZE-FLU combination product (TEST) compared to a similar formulation without containing FLU (i.e. AZE alone; REF). The secondary objectives are to compare the relative bioavailability (AUC0-∞) of AZE when administered either as fixed AZE-FLU combination product (TEST) or as marketed AZE product Astelin® Nasal Spray (COMP); To compare the effects of FLU on other pharmacokinetic parameters of AZE (AUC0-tlast, CL/f, Cmax, tmax, t½); To assess adverse events. |
| NCT01190852 ↗ | Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays | Completed | Prolytic GmbH | Phase 1 | 2010-08-01 | The primary objective is to assess the effect of fluticasone propionate (FLU) on the relative bioavailability (AUC0-∞) of azelastine hydrochloride (AZE) when administered as fixed AZE-FLU combination product (TEST) compared to a similar formulation without containing FLU (i.e. AZE alone; REF). The secondary objectives are to compare the relative bioavailability (AUC0-∞) of AZE when administered either as fixed AZE-FLU combination product (TEST) or as marketed AZE product Astelin® Nasal Spray (COMP); To compare the effects of FLU on other pharmacokinetic parameters of AZE (AUC0-tlast, CL/f, Cmax, tmax, t½); To assess adverse events. |
| NCT01190852 ↗ | Single Dose Pharmacokinetics of Intranasal Azelastine Delivered by a Fixed Combination With Fluticasone in Comparison to Azelastine Nasal Sprays | Completed | MEDA Pharma GmbH & Co. KG | Phase 1 | 2010-08-01 | The primary objective is to assess the effect of fluticasone propionate (FLU) on the relative bioavailability (AUC0-∞) of azelastine hydrochloride (AZE) when administered as fixed AZE-FLU combination product (TEST) compared to a similar formulation without containing FLU (i.e. AZE alone; REF). The secondary objectives are to compare the relative bioavailability (AUC0-∞) of AZE when administered either as fixed AZE-FLU combination product (TEST) or as marketed AZE product Astelin® Nasal Spray (COMP); To compare the effects of FLU on other pharmacokinetic parameters of AZE (AUC0-tlast, CL/f, Cmax, tmax, t½); To assess adverse events. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Condition Name
Condition MeSH
Clinical Trial Locations for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Trials by Country
Clinical Trial Progress for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Clinical Trial Phase
Clinical Trial Sponsors for AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE
Sponsor Name
